Autologous CD1c+ BDCA-1+ Myeloid Dendritic Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Autologous CD1c+ BDCA-1+ Myeloid Dendritic Cells, covering 2025-01-20 to 2025-01-20. Get the full timeline:
Most recent: Clinical Trial Update: Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab [Phase 1, Phase 2]